Type 2 diabetes in familial hypercholesterolaemia: another look at traditional risk factors
- PMID: 39374600
- DOI: 10.1016/S2213-8587(24)00247-X
Type 2 diabetes in familial hypercholesterolaemia: another look at traditional risk factors
Conflict of interest statement
MC declares grant support for clinical trials on homozygous familial hypercholesterolaemia from Regeneron Pharmaceuticals and Regenxbio; and consulting and lecture fees from Ultragenyx and Chiesi. AB declares grant support for clinical trials on lipoprotein(a) and other forms of dyslipidaemia from Alexion, Amgen, Eli Lilly, Ionis, Kaneka Medical, NewAmsterdam Pharma, Novartis, and Regeneron; and consulting and lecture fees from Kaneka Medical, Ionis, Novartis, and Regeneron.
Comment on
-
Association of BMI, lipid-lowering medication, and age with prevalence of type 2 diabetes in adults with heterozygous familial hypercholesterolaemia: a worldwide cross-sectional study.Lancet Diabetes Endocrinol. 2024 Nov;12(11):811-823. doi: 10.1016/S2213-8587(24)00221-3. Epub 2024 Oct 4. Lancet Diabetes Endocrinol. 2024. PMID: 39374602
Publication types
LinkOut - more resources
Full Text Sources